Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

BACKGROUND: New treatments have improved outcomes for patients with relapsed chronic lymphocytic leukemia (CLL), but complete remissions remain uncommon. Venetoclax has a distinct mechanism of action; it targets BCL2, a protein central to the survival of CLL cells. METHODS: We conducted a phase 1 do...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:N Engl J Med
Hauptverfasser: Roberts, Andrew W., Davids, Matthew S., Pagel, John M., Kahl, Brad S., Puvvada, Soham D., Gerecitano, John F., Kipps, Thomas J., Anderson, Mary Ann, Brown, Jennifer R., Gressick, Lori, Wong, Shekman, Dunbar, Martin, Zhu, Ming, Desai, Monali B., Cerri, Elisa, Enschede, Sari Heitner, Humerickhouse, Rod A., Wierda, William G., Seymour, John F.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2015
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7107002/
https://ncbi.nlm.nih.gov/pubmed/26639348
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1513257
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge